Literature DB >> 19008104

Predicting long-term outcome in poor grade aneurysmal subarachnoid haemorrhage patients utilising the Glasgow Coma Scale.

Robert M Starke1, Ricardo J Komotar, Marc L Otten, J Michael Schmidt, Luis D Fernandez, Fred Rincon, Errol Gordon, Neeraj Badjatia, Stephan A Mayer, E Sander Connolly.   

Abstract

The Glasgow Coma Scale (GCS) is the most universally accepted system for grading level of consciousness. Predicting outcome is particularly difficult in poor grade aneurysmal subarachnoid haemorrhage (aSAH) patients. We hypothesised that the GCS and individual examination components would correlate with long-term outcome and have varying prognostic value depending on assessment time points. GCS scores of 160 aSAH patients presenting in stupor or coma were prospectively recorded on admission and each subsequent day until hospital day 14. Early treatment was planned for each patient unless the patient's family refused aggressive intervention or the patient died before surgery. Outcomes were assessed by the modified Rankin scale (mRS) at 14 days, 3 months, and one year. All patients who did not receive surgical treatment died within one year. Of the 104 patients who received surgical treatment, 13.5% of them had a favourable outcome at 14 days, 38.5% at 3 months, and 51% at one year (p<0.0001). Admission GCS scores significantly correlated with outcome (Spearman rank test, rs=0.472, p<0.0001). On admission, motor examination correlated best with one-year outcome (rs=0.533, p<0.0001). Each point increase in motor examination predicted a 1.8-fold increased odds of favourable long-term outcome (95% confidence interval [CI], 1.4-2.3). At discharge, eye examination (rs=0.760, p<0.0001) correlated best with one-year outcome, and a one point increase in eye examination predicted a 3.1-fold increased odds of favourable outcome (95% CI, 1.8-5.4). During hospitalisation, the best eye exam (rs=0.738, p<0.0001) and worst motor exam (rs=0.612, p<0.0001) were the most highly correlated with the one-year outcome. Long-term follow-up is necessary when evaluating recovery after aSAH, as outcomes improve significantly during the first year. The GCS and its individual components correlate well with long-term outcome. Admission motor examination and spontaneous eye opening during hospitalisation are most predictive of favourable recovery.

Entities:  

Mesh:

Year:  2008        PMID: 19008104     DOI: 10.1016/j.jocn.2008.02.010

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  11 in total

1.  Time course of outcome in poor grade subarachnoid hemorrhage patients: a longitudinal retrospective study.

Authors:  Elisa Gouvêa Bogossian; Daniela Diaferia; Andrea Minini; Narcisse Ndieugnou Djangang; Marco Menozzi; Lorenzo Peluso; Filippo Annoni; Jacques Creteur; Sophie Schuind; Olivier Dewitte; Fabio Silvio Taccone
Journal:  BMC Neurol       Date:  2021-05-13       Impact factor: 2.474

2.  20-HETE is associated with unfavorable outcomes in subarachnoid hemorrhage patients.

Authors:  Mark K Donnelly; Elizabeth A Crago; Yvette P Conley; Jeffery R Balzer; Dianxu Ren; Andrew F Ducruet; Patrick M Kochanek; Paula R Sherwood; Samuel M Poloyac
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-29       Impact factor: 6.200

3.  Glasgow Coma Scale Score Fluctuations are Inversely Associated With a NIRS-based Index of Cerebral Autoregulation in Acutely Comatose Patients.

Authors:  Ryan J Healy; Andres Zorrilla-Vaca; Wendy Ziai; Marek A Mirski; Charles W Hogue; Romergryko Geocadin; Batya Radzik; Caitlin Palmisano; Lucia Rivera-Lara
Journal:  J Neurosurg Anesthesiol       Date:  2019-07       Impact factor: 3.956

4.  Coping strategies, health-related quality of life and psychiatric history in patients with aneurysmal subarachnoid haemorrhage.

Authors:  Mathilde Hedlund; Elisabeth Ronne-Engström; Marianne Carlsson; Lisa Ekselius
Journal:  Acta Neurochir (Wien)       Date:  2010-05-05       Impact factor: 2.216

5.  Prediction of two month modified Rankin Scale with an ordinal prediction model in patients with aneurysmal subarachnoid haemorrhage.

Authors:  Roelof Risselada; Hester F Lingsma; Andrew J Molyneux; Richard S C Kerr; Julia Yarnold; Mary Sneade; Ewout W Steyerberg; Miriam C J M Sturkenboom
Journal:  BMC Med Res Methodol       Date:  2010-09-29       Impact factor: 4.615

Review 6.  Functional Outcome After Poor-Grade Subarachnoid Hemorrhage: A Single-Center Study and Systematic Literature Review.

Authors:  Airton Leonardo de Oliveira Manoel; Ann Mansur; Gisele Sampaio Silva; Menno R Germans; Blessing N R Jaja; Ekaterina Kouzmina; Thomas R Marotta; Simon Abrahamson; Tom A Schweizer; Julian Spears; R Loch Macdonald
Journal:  Neurocrit Care       Date:  2016-12       Impact factor: 3.210

7.  Modified Glasgow coma scale for predicting outcome after subarachnoid hemorrhage surgery.

Authors:  In-Suk Bae; Hyoung-Joon Chun; Kyu-Sun Choi; Hyeong-Joong Yi
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

8.  Elevated high-sensitive troponin T on admission is an indicator of poor long-term outcome in patients with subarachnoid haemorrhage: a prospective observational study.

Authors:  Jonatan Oras; Christina Grivans; Andreas Bartley; Bertil Rydenhag; Sven-Erik Ricksten; Helene Seeman-Lodding
Journal:  Crit Care       Date:  2016-01-19       Impact factor: 9.097

9.  Ratio of Nitric Oxide Metabolite Levels in Cerebrospinal Fluid and Serum, and Their Correlation with Severity and Outcome in Patients with Subarachnoid Haemorrhage.

Authors:  Giat Seng Kho; Regunath Kandasamy; Mohamad Adam Bujang; Mummedy Swammy; Muzaimi Mustapha; Jafri Malin Abdullah
Journal:  Malays J Med Sci       Date:  2021-12-22

10.  The Local Intraarterial Administration of Nimodipine Might Positively Affect Clinical Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia.

Authors:  Johannes Walter; Martin Grutza; Markus Möhlenbruch; Dominik Vollherbst; Lidia Vogt; Andreas Unterberg; Klaus Zweckberger
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.